Steroid-sparing effect of Adalimumab monotherapy in non-infectious uveitis
Purpose
To evaluate the steroid-sparing effect of adalimumab (ADA) monotherapy in non-infectious uveitis.
Methods
This study included patients with non-infectious uveitis who required prednisolone ≥ 5 mg/day for controlling inflammation and were treated with ADA monotherapy. For patients who experienced uveitis flare-ups during steroid tapering, methotrexate was added concomitantly with ADA. We also assessed the efficacy of MTX as well.
Results
The study included 38 patients (17 females). The most common disease was Vogt-Koyanagi-Harada (VKH) disease (11 patients), followed by retinal vasculitis (9 patients) and Behçet's disease (7 patients). The mean systemic steroid dose before ADA induction was 15.2 mg/day. While 30 patients could taper off steroids, 8 (21.1%) patients relapsed during steroid reduction. VKH disease was the most common relapse in 5 patients, followed by Behçet's disease, retinal vasculitis, and posterior scleritis in 1 patient each. Six out of 8 relapsed patients received concomitant MTX, and three were able to wean off steroids.
Conclusion
About 80% of the patients were able to taper off steroids with the ADA monoterapy. In cases that relapse by ADA monotherapy, VKH disease was the most common. However, the addition of MTX to ADA treatment enable to taper off steroid in half of these cases.
Conflict of interest
No
Authors 1
Last name
HARADA
Initials of first name(s)
Y
Department
Hiroshima University
City
Hiroshima
Country
Japan
Authors 2
Last name
Hiyama
Initials of first name(s)
T
Department
Hiroshima University
City
Hiroshima
Country
Japan
Authors 3
Last name
Sada
Initials of first name(s)
I
Department
Hiroshima University
City
Hiroshima
Country
Japan
Authors 4
Last name
Kiuchi
Initials of first name(s)
Y
Department
Hiroshima Univerisity
City
Hiroshima
Country
Japan
This website uses cookies to ensure you get the best experience on our website.
Learn more